Business
Capital Markets Event
Capital Markets Event.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 9287M Futura Medical PLC 26 January 2016 \n\n\n\n\n\nFor immediate release \n\n\n26 January 2016\n\n\n\n\n \n \nFutura Medical plc\n(\"Futura\" or the \"Company\")\n \nCapital Markets Event\n \n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will this afternoon host a capital markets event for equity analysts and institutional investors. \n \nThe event will be webcast. To access the webcast live, please log on to the following web address approximately 5 minutes before 3.15pm GMT today:\nhttp://vm.buchanan.uk.com/2016/futuramedical260116/registration.htm\n \nA recording of the webcast will be made available for several days from 27 January 2016 at www.futuramedical.com and at www.buchanan.uk.com.\n \nThe capital markets event will provide details of progress across the Company's portfolio of products. On CSD500, Futura's erectogenic condom, attendees of the event will be informed that the Company continues to receive positive stability data from its modified manufacturing process. This data indicates an extended shelf life for the product in line with distributors' requirements.\n \nThe presentations on MED2002, Futura's novel gel for erectile dysfunction, will include an update on recruitment to the current pivotal clinical study, which now has a total of 171 patients enrolled in the run-in phase of the study. The announcement of headline data from the study remains on track for the end of H1 2016.\n \nPresentations on the Company's topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen), will include an overview of the potential regulatory pathway for the products, which remains in line with previous announcements, as well as an outline of the likely commercialisation strategy. \n \nAnalysts and investors who would like to attend the capital markets event, please contact Buchanan at the details below.\n \nFor further information please contact:\n\n\n\n\nFutura Medical plc\n\n\n\n\n\n\n\nJames Barder, Chief Executive\n\n\nTel: +44 (0) 1483 685 670\n\n\n\n\nEmail to: [email protected]\n\n\nwww.futuramedical.com \n\n\n\n\n \nN+1 Singer (Nominated Adviser and Broker)\n\n\n\n\n\n\n\nAubrey Powell / Liz Yong / Tom Smale\nCorporate Finance \n...